Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

被引:100
作者
Busse, W
Nelson, H
Wolfe, J
Kalberg, C
Yancey, SW
Rickard, KA
机构
[1] Univ Wisconsin, Sch Med, Dept Med, Clin Sci Ctr 15 220, Madison, WI 53792 USA
[2] Natl Jewish Med & Res Ctr, Denver, CO USA
[3] Allergy & Asthma Associates, Santa Clara Valley Res Ctr, San Jose, CA USA
[4] Glaxo Wellcome Inc, Res Triangle Pk, NC 27709 USA
关键词
salmeterol xinafoate; zafirlukast; asthma; peak expiratory flow; beta(2)-agonist; leukotriene receptor antagonist;
D O I
10.1016/S0091-6749(99)70182-X
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Background: Salmeterol, a long-acting beta(2)-agonist, and zafirlukast, a leukotriene receptor antagonist, are both indicated for the treatment of asthma in adolescent and adult patients. Objective: We sought to compare the effect of 4 weeks of treatment with inhaled salmeterol xinafoate versus oral zafirlukast in the treatment of persistent asthma. Methods: This was a randomized, double-blind, double-dummy, parallel-group, multicenter clinical trial. Patients, over 80% of whom were on a concurrent inhaled corticosteroid regimen, were treated for 4 weeks with either inhaled salmeterol xinafoate 42 mu g twice daily administered by means of a metered dose inhaler or oral zafirlukast 20 mg twice daily. The primary efficacy measure was morning peak expiratory flow (PEF); secondary efficacy measures included evening PEF, asthma symptom scores, supplemental albuterol use, nighttime awakenings, sleep symptoms, asthma exacerbations, and FEV1. Results: Both inhaled salmeterol and oral zafirlukast resulted in within-group improvements from baseline in measures of pulmonary function, asthma symptoms, and supplemental albuterol use. Salmeterol treatment resulted in significantly greater improvements from baseline compared with zafirlukast for most efficacy measurements, including morning PEF (29.6 vs 13.0 L/min; P less than or equal to .001), percentage of symptom-free days (22.4% vs 8.8%; P less than or equal to .001), and percentage of days and nights with no supplemental albuterol use (30.5% vs 11.3%; P less than or equal to .001), There were no differences in safety profiles as assessed by adverse event monitoring. Conclusion: In patients with persistent asthma, most of whom were concurrently using inhaled corticosteroids, treatment with inhaled salmeterol provided significantly greater improvement than oral zafirlukast in overall asthma control over the 4-week treatment period.
引用
收藏
页码:1075 / 1080
页数:6
相关论文
共 50 条
[41]   Comparison of the effects of tulobuterol patch and salmeterol in moderate to severe asthma [J].
Nishiyama, Osamu ;
Taniguchi, Hiroyuki ;
Kondoh, Yasuhiro ;
Kimura, Tomoki ;
Kato, Keisuke ;
Kume, Hiroaki ;
Shimokata, Kaoru .
CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2006, 33 (11) :1016-1021
[42]   INHALED SALMETEROL AND ALBUTEROL IN ASTHMATIC-PATIENTS RECEIVING HIGH-DOSE INHALED CORTICOSTEROIDS [J].
LAI, CKW ;
CHAN, CHS ;
HO, SS ;
HUI, ACF ;
LAI, KN .
CHEST, 1995, 108 (01) :36-40
[43]   Comparison of zafirlukast (Accolate®) absorption after oral and colonic administration in humans [J].
Fischer, JD ;
Song, MH ;
Suttle, AB ;
Heizer, WD ;
Burns, CB ;
Vargo, DL ;
Brouwer, KLR .
PHARMACEUTICAL RESEARCH, 2000, 17 (02) :154-159
[44]   Comparison of vilanterol, a novel long-acting beta(2) agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids [J].
Lotvall, Jan ;
Bateman, Eric D. ;
Busse, William W. ;
O'Byrne, Paul M. ;
Woodcock, Ashley ;
Toler, William T. ;
Jacques, Loretta ;
Goldfrad, Caroline ;
Bleecker, Eugene R. .
JOURNAL OF NEGATIVE RESULTS IN BIOMEDICINE, 2014, 13
[45]   Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events [J].
O'Shea, Orlagh ;
Stovold, Elizabeth ;
Cates, Christopher J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2021, (04)
[46]   Salmeterol in paediatric asthma [J].
Byrnes, C ;
Shrewsbury, S ;
Barnes, PJ ;
Bush, A .
THORAX, 2000, 55 (09) :780-784
[47]   Zafirlukast for symptomatic mild-to-moderate asthma: A 13-week multicenter study [J].
Fish, JE ;
Kemp, JP ;
Lockey, RF ;
Glass, M ;
Hanby, LA ;
Bonuccelli, CM ;
Bronsky, E ;
Condemi, J ;
Goldstein, S ;
Norton, J ;
Rosenthal, R ;
Silvers, W ;
Tinkelman, D ;
Weisberg, S ;
Winder, J .
CLINICAL THERAPEUTICS, 1997, 19 (04) :675-690
[49]   The effects of the combination of inhaled ipratropium and oral theophylline in asthma [J].
Burki, NK .
CHEST, 1997, 111 (06) :1509-1513
[50]   Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone [J].
Baumgartner, RA ;
Martinez, G ;
Edelman, JM ;
Gomez, GGR ;
Bernstein, M ;
Bird, S ;
Angner, R ;
Polis, A ;
Dass, SB ;
Lu, S ;
Reiss, TF .
EUROPEAN RESPIRATORY JOURNAL, 2003, 21 (01) :123-128